CCM Biosciences

Innovative, cutting-edge therapeutics & diagnostics for unmet medical needs. Deeply rooted in science from PMC Advanced Technology (

[CCM Biosciences @ccm_bio]

Join CCM Biosciences at @ASCO 2025 as they unveil their 4th-gen EGFR inhibitors for non-small cell lung cancer (NSCLC)—designed to overcome inevitable resistance to current 3rd-gen tyrosine kinase inhibitors (TKIs).

A new path forward in lung cancer care to address the leading cause of cancer death globally.

Read more here: https://t.co/zIu61Euj2V

#NSCLC #EGFR #Oncology #CancerInnovation #ASCO25

[CCM Biosciences @ccm_bio]

CCM Biosciences will unveil their next-gen FLT3 inhibitor for AML at @ASCO 2025! Designed to overcome resistance, the inhibitor outperforms several current therapies—with and without FLT3 resistance mutations—across multiple animal models of AML.

Read more: https://t.co/jFZSKnJOGK

#AML #FLT3 #LeukemiaResearch #TargetedTherapy #OncologyInnovation #ASCO25

[CCM Biosciences @ccm_bio]

In early 2024, Dr. George Vlasuk (@GVlasuk)—former CEO of longevity therapeutic biotech companies Sirtris Pharma and Navitor Pharma—met with Dr. Raj Chakrabarti, former Prof. of ChemE at CMU and founder/CEO of CCM Biosciences, to discuss the challenge of sirtuin enzyme activation. Their conversation was sparked by a recent CCM Biosciences paper addressing this longstanding problem, now published in the flagship journal of the American Physical Society (APS), the world’s leading physics research organization.

They discussed how Sirtris—co-founded by Harvard professor @davidasinclair and acquired by GSK for $720 million—had aimed to activate the major mitochondrial sirtuin, SIRT3, but lacked a clear approach at the time. Dr. Chakrabarti discusses the solution here: https://t.co/zatr1XhZpE.

[CCM Biosciences @ccm_bio]

In 2017 one of the pioneers in aging research, MIT Professor of Biology Leonard Guarente, met with the research group of Dr. Raj Chakrabarti founder/CEO of CCM Biosciences and former CMU Professor of Chemical Engineering, regarding this paper -- https://t.co/gbFi6yJl7Y – which asked the question: how can the sensitivity of sirtuin enzymes to NAD+ be enhanced pharmaceutically to combat age-related diseases?

In 2024 the solution to the problem was finally reported by CCM Biosciences and its affiliated basic research center, Chakrabarti Advanced Technology.

Read about it here: https://t.co/zatr1XhrA6

[CCM Biosciences @ccm_bio]

An important new page in the history of sirtuin enzyme research – a topic recently discussed by @davidasinclair and @GVlasuk – involves the development of a unified biophysical framework for the pharmaceutical activation of sirtuin enzymes and the discovery of the first true steady-state activators of the major mitochondrial sirtuin SIRT3.

Read about it in an interview with principal investigator and former CMU Professor of Chemical Engineering, Dr. Raj Chakrabarti: https://t.co/zatr1XhZpE

[CCM Biosciences @ccm_bio]

Breaking barriers in #longevityscience—CCM Biosciences has discovered first-in-class enzyme activators that rejuvenate a previously undruggable mitochondrial regulator of aging.

Dr. Raj Chakrabarti, CEO of CCM Biosciences and former Professor of Chemical Engineering at Carnegie Mellon University, discusses how this breakthrough could enable an entirely new approach to the treatment of age-related diseases: https://t.co/zatr1XhZpE

[CCM Biosciences @ccm_bio]

We’re inspired by the recent announcement of the $101M award from #XPrize for #AgingTherapies—an exciting step toward revolutionizing treatments for the elderly. We look forward to seeing the innovative therapeutics advancing to clinical trials in 2026!

For more information: https://t.co/PYNZ70hpzH

#LongevityResearch #HealthyAging

[CCM Biosciences @ccm_bio]

CCM Biosciences discovers non-allosteric activators of the “undruggable” enzyme Sirtuin-3, unlocking new potential in cell rejuvenation.

Learn more: https://t.co/Gyv7vehpAe

#CCMBiosciences #CellRejuvenation #Sirtuin3 #DrugDiscovery

[David Sinclair @davidasinclair]

Congrats 👏

Here’s what diseases activation of NAD-dependent SIRT3 might prevent or treat - and how to activate it…

[Dr Singularity @Dr_Singularity]

HUGE Anti-Aging / Longevity Breakthrough

Scientists restore 'Youthful' enzyme activity to combat aging

"CCM Biosciences has developed groundbreaking compounds that activate the enzyme SIRT3, potentially reversing age related cellular decline."

'They outperform existing treatments and will enter clinical trials in 2025 to target Alzheimer’s, Parkinson’s, and other age related diseases.'

I’ll say it again because it’s crucial—clinical trials are happening this year.

"These first in class compounds restore the enzyme’s activity to levels comparable to those of youthful cells, offering substantial potential for clinical applications in treating age related disorders"

“Efforts have been underway for decades to activate signaling pathways regulated by sirtuins to combat age related disorders, but prior efforts have encountered significant hurdles. The discoveries by CCM Biosciences pertaining to the design of drug candidates that can activate the major mitochondrial pathways regulated by sirtuins, along with the clinical development plan for evaluation of efficacy as well as safety of these drug candidates, revitalize this area of drug development.” - said Dr. Michael Pollak, Professor of Medicine, Oncology, and Pharmacology at McGill University

[CCM Biosciences @ccm_bio]

Researchers from CCM Biosciences, Inc., discover first-in-class non-allosteric activators of the previously undruggable enzyme Sirtuin-3.

Explore the landmark work towards cell rejuvenation here: https://t.co/mQO0jrUhzg

#CCMBiosciences #CellRejuvenation #Sirtuin #EnzymeActivation #AllostericModulation #DrugDiscovery

[CCM Biosciences @ccm_bio]

CCM Biosciences identifies novel enzyme activators with applications in longevity space https://t.co/BmICfY6nN7 via @mcgillu

[CCM Biosciences @ccm_bio]

Researchers at CCM Biosciences, Inc. and Chakrabarti Advanced Technology have discovered enzyme activators to restore levels of the major #MitochondrialSirtuin called #SIRT3. This can help mitigate disorders like #Alzheimer’s.

Read more: https://t.co/Gyv7vehpAe

[CCM Biosciences @ccm_bio]

In a new @PhysRevX study, researchers from CCM Biosciences, Inc. and Chakrabarti Advanced Technology have discovered #Nonallosteric activators of the #MitochondrialSirtuinEnzyme called #SIRT3 that can cure #AgerelatedDisorders.

Read more: https://t.co/Gyv7vegRKG

[CCM Biosciences @ccm_bio]

McGill Desautels Finance Professor Anisha Ghosh Founds Diversified Biotechnology Company With Over US$25M Funding

https://t.co/h5KETPKMta

https://t.co/Oiujb9nggT

#Portfolio

[McGill Desautels @DesautelsMcGill]

Prof. Anisha Ghosh has leveraged her research at the intersection of finance, economics & statistical inference to co-found CCM Bio, a diversified #biotech company, w/ the global chemical & #pharmaceutical conglomerate PMC Group, Inc. CCM Bio. https://t.co/dXFA1ip2HL

[CCM Biosciences @ccm_bio]

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit

https://t.co/n2xUKxlGcC

#Genomics
#synbio

[CCM Biosciences @ccm_bio]

CCM Biosciences Announces Launch of Protein Upregulation Business Unit

https://t.co/gJ0SHudvKx

#longevity
#drugdiscovery

[CCM Biosciences @ccm_bio]

CCM Biosciences Launches from Stealth to Advance Portfolio of Proprietary, First-in-Class Therapies and Companion Diagnostic Tests Across Multiple Therapeutic Areas

https://t.co/elB9aPbncz

#biotech